{"id":76092,"date":"2026-10-08T04:18:05","date_gmt":"2026-10-08T04:18:05","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=76092"},"modified":"2026-10-08T04:18:05","modified_gmt":"2026-10-08T04:18:05","slug":"u-s-analyst-updates-october-7th-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/","title":{"rendered":"U.S. Analyst Updates: October 7th, 2026"},"content":{"rendered":"

Analyst Ratings (USA)<\/a><\/h2>\n

American analyst updates for today show selective optimism in AI infrastructure, cybersecurity and healthcare, alongside caution across transportation, housing-related businesses and insurance. Marvell and Zscaler received numerous target increases, while healthcare coverage initiations highlighted opportunities in medical technology. However, target reductions across airlines and freight operators, plus downgrades in building products, suggest a less uniform outlook for economically sensitive sectors.<\/p>\n

Analyst Updates (463)<\/h2>\n

10x Genomics (TXG)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$110.00 from US$52.00.<\/p>\n

Abbott Laboratories (ABT)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$120.00.<\/p>\n

AbbVie (ABBV)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and raised its price target to US$310.00 from US$296.00.<\/p>\n

Abercrombie & Fitch (ANF)<\/strong> \u2014 BTIG Research reiterated its Buy rating and a price target of US$175.00.<\/p>\n

Adeia (ADEA)<\/strong> \u2014 BWS Financial reiterated its Buy rating and a price target of US$50.00.<\/p>\n

Adient (ADNT)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$23.00 from US$29.00.<\/p>\n

Aflac (AFL)<\/strong> \u2014 Barclays reiterated its Underweight rating and raised its price target to US$101.00 from US$99.00.<\/p>\n

Aflac (AFL)<\/strong> \u2014 Mizuho maintained its Underperform rating and lowered its price target to US$107.00 from US$116.00.<\/p>\n

Afya (AFYA)<\/strong> \u2014 JPMorgan upgraded its rating to Overweight from Neutral and lowered its price target to US$19.00 from US$21.00.<\/p>\n

Agilent Technologies (A)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$195.00 from US$175.00.<\/p>\n

Agios Pharmaceuticals (AGIO)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$37.00 from US$39.00.<\/p>\n

Air Products and Chemicals (APD)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$312.00 from US$330.00.<\/p>\n

Airbnb (ABNB)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$185.00 from US$186.00.<\/p>\n

Alaska Air Group (ALK)<\/strong> \u2014 Susquehanna maintained its Positive rating and lowered its price target to US$50.00 from US$55.00.<\/p>\n

Albemarle (ALB)<\/strong> \u2014 Argus maintained its Buy rating and lowered its price target to US$135.00 from US$230.00.<\/p>\n

Albertsons Companies (ACI)<\/strong> \u2014 RBC Capital Markets reiterated its Outperform rating and a price target of US$13.00.<\/p>\n

Alcoa (AA)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$50.00 from US$52.00.<\/p>\n

Alcoa (AA)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$50.00 from US$53.00.<\/p>\n

Alcon (ALC)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$70.00.<\/p>\n

Allegiant Travel (ALGT)<\/strong> \u2014 Raymond James reiterated its Strong Buy rating and a price target of US$110.00.<\/p>\n

Allegiant Travel (ALGT)<\/strong> \u2014 Susquehanna maintained its Neutral rating and lowered its price target to US$85.00 from US$110.00.<\/p>\n

Allstate (ALL)<\/strong> \u2014 Barclays maintained its Underweight rating and lowered its price target to US$221.00 from US$226.00.<\/p>\n

Allstate (ALL)<\/strong> \u2014 HSBC upgraded its rating to Buy from Hold with a price target of US$266.00.<\/p>\n

Allstate (ALL)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$295.00 from US$300.00.<\/p>\n

Ambev (ABEV)<\/strong> \u2014 BofA Securities downgraded its rating to Underperform from Neutral with a price target of US$3.30.<\/p>\n

Ambiq Micro (AMBQ)<\/strong> \u2014 Jefferies initiated coverage with a Buy rating and a price target of US$90.00.<\/p>\n

American Airlines Group (AAL)<\/strong> \u2014 Susquehanna maintained its Positive rating and lowered its price target to US$15.00 from US$20.00.<\/p>\n

American Axle & Manufacturing (DCH)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$8.00 from US$9.00.<\/p>\n

American International Group (AIG)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$83.00 from US$85.00.<\/p>\n

AMETEK (AME)<\/strong> \u2014 DA Davidson set its price target at US$285.00.<\/p>\n

Amgen (AMGN)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$359.00 from US$362.00.<\/p>\n

Amgen (AMGN)<\/strong> \u2014 Truist Securities maintained its Hold rating and raised its price target to US$380.00 from US$362.00.<\/p>\n

Amphenol (APH)<\/strong> \u2014 UBS reiterated its Buy rating and raised its price target to US$105.00 from US$99.00.<\/p>\n

Anteris Technologies Global Corp. (AVR)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$10.00.<\/p>\n

AON (AON)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$317.00 from US$382.00.<\/p>\n

AON (AON)<\/strong> \u2014 Cantor Fitzgerald maintained its Overweight rating and lowered its price target to US$400.00 from US$433.00.<\/p>\n

AON (AON)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$324.00 from US$366.00.<\/p>\n

AppFolio (APPF)<\/strong> \u2014 UBS downgraded its rating to Neutral from Buy and raised its price target to US$220.00 from US$200.00.<\/p>\n

AptarGroup (ATR)<\/strong> \u2014 Deutsche Bank initiated coverage with a Buy rating and a price target of US$150.00.<\/p>\n

Aptiv (APTV)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$57.00 from US$62.00.<\/p>\n

ArcBest (ARCB)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$170.00 from US$173.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

ArcBest (ARCB)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$160.00 from US$165.00.<\/p>\n

Arch Capital Group (ACGL)<\/strong> \u2014 Cantor Fitzgerald maintained its Neutral rating and lowered its price target to US$105.00 from US$110.00.<\/p>\n

Arista Networks (ANET)<\/strong> \u2014 Evercore ISI reiterated its Outperform rating.<\/p>\n

ArriVent BioPharma (AVBP)<\/strong> \u2014 BTIG Research maintained its Buy rating and lowered its price target to US$29.00 from US$42.00.<\/p>\n

ArriVent BioPharma (AVBP)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$20.00 from US$40.00.<\/p>\n

ArriVent BioPharma (AVBP)<\/strong> \u2014 Guggenheim maintained its Buy rating and lowered its price target to US$18.00 from US$45.00.<\/p>\n

ArriVent BioPharma (AVBP)<\/strong> \u2014 JonesTrading maintained its Buy rating and lowered its price target to US$22.00 from US$45.00.<\/p>\n

Arthur J. Gallagher & Co. (AJG)<\/strong> \u2014 Cantor Fitzgerald maintained its Neutral rating and lowered its price target to US$280.00 from US$300.00.<\/p>\n

Arthur J. Gallagher & Co. (AJG)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$271.00 from US$292.00.<\/p>\n

Arthur J. Gallagher & Co. (AJG)<\/strong> \u2014 Oppenheimer initiated coverage with a Perform rating (Market Perform in the other feed).<\/p>\n

Asbury Automotive Group (ABG)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$193.00 from US$250.00.<\/p>\n

ASML (ASML)<\/strong> \u2014 RBC Capital Markets reiterated its Outperform rating and a price target of US$2,100.00.<\/p>\n

AT&T (T)<\/strong> \u2014 KeyBanc Capital Markets reiterated its Overweight rating and a price target of US$36.00.<\/p>\n

Atour Lifestyle (ATAT)<\/strong> \u2014 HSBC initiated coverage with a Buy rating and a price target of US$39.70.<\/p>\n

AutoNation (AN)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$213.00 from US$248.00.<\/p>\n

Avantor (AVTR)<\/strong> \u2014 Barclays maintained its Underweight rating and raised its price target to US$15.00 from US$13.00.<\/p>\n

Axis Capital (AXS)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$116.00 from US$118.00.<\/p>\n

AxoGen (AXGN)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$55.00.<\/p>\n

Bausch + Lomb (BLCO)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$24.00.<\/p>\n

Baxter International (BAX)<\/strong> \u2014 Barclays initiated coverage with an Underweight rating and a price target of US$20.00.<\/p>\n

Beasley Broadcast Group (BBGI)<\/strong> \u2014 Noble Financial reiterated its Outperform rating.<\/p>\n

Becton, Dickinson and Company (BDX)<\/strong> \u2014 Barclays initiated coverage with an Underweight rating and a price target of US$165.00.<\/p>\n

BeOne Medicines (ONC)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$420.00 from US$418.00.<\/p>\n

Beta Bionics (BBNX)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$30.00.<\/p>\n

Better Home & Finance (BETR)<\/strong> \u2014 Cantor Fitzgerald changed its rating to Overweight from Hold.<\/p>\n

Better Home & Finance (BETR)<\/strong> \u2014 Northland Securities set its price target at US$18.00.<\/p>\n

Biomea Fusion (BMEA)<\/strong> \u2014 Brookline Capital Markets initiated coverage with a Buy rating.<\/p>\n

BioNTech (BNTX)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$114.00 from US$115.00.<\/p>\n

Black Hills (BKH)<\/strong> \u2014 Freedom Broker upgraded its rating to Buy from Hold and raised its price target to US$78.00 from US$69.00.<\/p>\n

BlackRock (BLK)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$1,420.00 from US$1,450.00.<\/p>\n

BlackRock (BLK)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$1,277.00 from US$1,320.00.<\/p>\n

Bloom Energy (BE)<\/strong> \u2014 Bernstein reiterated its Market Perform rating and a price target of US$282.00.<\/p>\n

Bloom Energy (BE)<\/strong> \u2014 UBS maintained its Buy rating and raised its price target to US$350.00 from US$325.00.<\/p>\n

Booking (BKNG)<\/strong> \u2014 Wells Fargo reiterated its Reduce rating and lowered its price target to US$190.00 from US$220.00.<\/p>\n

Booz Allen Hamilton (BAH)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$77.00 from US$82.00.<\/p>\n

Booz Allen Hamilton (BAH)<\/strong> \u2014 Jefferies maintained its Hold rating and lowered its price target to US$75.00 from US$80.00.<\/p>\n

BorgWarner (BWA)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$91.00 from US$95.00.<\/p>\n

Boston Scientific (BSX)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$48.00.<\/p>\n

Boyd Gaming (BYD)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$102.00 from US$104.00.<\/p>\n

BridgeBio Pharma (BBIO)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$156.00 from US$157.00.<\/p>\n

BrightSpire Capital (BRSP)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

BrightSpire Capital (BRSP)<\/strong> \u2014 Citizens JMP Securities maintained its Market Outperform rating and lowered its price target to US$6.00 from US$7.00.<\/p>\n

BrightSpire Capital (BRSP)<\/strong> \u2014 Goldman Sachs upgraded its rating to Buy.<\/p>\n

Bristol Myers Squibb (BMY)<\/strong> \u2014 Morgan Stanley reiterated its Underweight rating and raised its price target to US$41.00 from US$40.00.<\/p>\n

Brixmor Property Group (BRX)<\/strong> \u2014 KeyBanc Capital Markets reiterated its Overweight rating and a price target of US$34.00.<\/p>\n

Brown & Brown (BRO)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$71.00 from US$76.00.<\/p>\n

Brown & Brown (BRO)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$78.00 from US$83.00.<\/p>\n

Brown & Brown (BRO)<\/strong> \u2014 Oppenheimer initiated coverage with an Outperform rating and a price target of US$73.00.<\/p>\n

Bruker (BRKR)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$70.00 from US$58.00.<\/p>\n

Builders FirstSource (BLDR)<\/strong> \u2014 RBC Capital Markets downgraded its rating to Sector Perform from Outperform with a price target of US$62.00.<\/p>\n

C.H. Robinson Worldwide (CHRW)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$200.00 from US$215.00.<\/p>\n

CACI International (CACI)<\/strong> \u2014 Citigroup maintained its Neutral rating and raised its price target to US$689.00 from US$648.00.<\/p>\n

Cadence Design Systems (CDNS)<\/strong> \u2014 Deutsche Bank reiterated its Buy rating and a price target of US$420.00.<\/p>\n

Canadian National Railway (CNI)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$143.00 from US$151.00.<\/p>\n

Canadian Pacific Kansas City (CP)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$102.00 from US$109.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

CarGurus (CARG)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$35.00 from US$40.00.<\/p>\n

Caribou Biosciences (CRBU)<\/strong> \u2014 Brookline Capital Markets changed its rating to Hold from Buy.<\/p>\n

Caribou Biosciences (CRBU)<\/strong> \u2014 Leerink Partners downgraded its rating to Market Perform from Outperform and lowered its price target to US$1.00 from US$4.00.<\/p>\n

Caribou Biosciences (CRBU)<\/strong> \u2014 RBC Capital Markets downgraded its rating to Sector Perform from Outperform with a price target of US$1.00.<\/p>\n

Carrier Global (CARR)<\/strong> \u2014 Bernstein maintained its Market Perform rating and lowered its price target to US$64.00 from US$78.00.<\/p>\n

Cars.com (CARS)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$11.50 from US$13.00.<\/p>\n

Cencora (COR)<\/strong> \u2014 Leerink Partners maintained its Outperform rating and raised its price target to US$388.00 from US$380.00.<\/p>\n

Certara (CERT)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$9.00 from US$7.50.<\/p>\n

Charles Schwab (SCHW)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$118.00 from US$125.00.<\/p>\n

Charles Schwab (SCHW)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$113.00 from US$128.00.<\/p>\n

Cheniere Energy (LNG)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$287.00 from US$279.00.<\/p>\n

Chubb (CB)<\/strong> \u2014 Cantor Fitzgerald maintained its Neutral rating and raised its price target to US$333.00 from US$330.00.<\/p>\n

Chubb (CB)<\/strong> \u2014 HSBC reiterated its Hold rating and a price target of US$359.00.<\/p>\n

Chubb (CB)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$336.00 from US$347.00.<\/p>\n

Citizens (CIZN)<\/strong> \u2014 Jefferies set its price target at US$14.00.<\/p>\n

Citizens Financial Group (CFG)<\/strong> \u2014 Raymond James resumed coverage with a Strong Buy rating and a price target of US$77.00.<\/p>\n

CLEAR Secure (YOU)<\/strong> \u2014 Needham reiterated its Buy rating and a price target of US$70.00.<\/p>\n

CME Group (CME)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$281.00 from US$270.00.<\/p>\n

Coinbase Global (COIN)<\/strong> \u2014 Barclays maintained its Underweight rating and raised its price target to US$149.00 from US$95.00.<\/p>\n

Coinbase Global (COIN)<\/strong> \u2014 BTIG Research reiterated its Buy rating and a price target of US$240.00.<\/p>\n

Coinbase Global (COIN)<\/strong> \u2014 Goldman Sachs reiterated its Buy rating and a price target of US$244.00.<\/p>\n

ConocoPhillips (COP)<\/strong> \u2014 Truist Securities maintained its Hold rating and raised its price target to US$136.00 from US$130.00.<\/p>\n

Consolidated Edison (ED)<\/strong> \u2014 Mizuho set its price target at US$108.00.<\/p>\n

Constellation Brands (STZ)<\/strong> \u2014 Citigroup listed a Negative outlook.<\/p>\n

Constellation Brands (STZ)<\/strong> \u2014 Goldman Sachs reiterated its Buy rating and a price target of US$155.00.<\/p>\n

Cooper (COO)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$60.00.<\/p>\n

Core & Main (CNM)<\/strong> \u2014 RBC Capital Markets maintained its Outperform rating and lowered its price target to US$57.00 from US$60.00.<\/p>\n

Corebridge Financial (CRBG)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$39.00 from US$33.00.<\/p>\n

Corebridge Financial (CRBG)<\/strong> \u2014 Mizuho maintained its Outperform rating and raised its price target to US$40.00 from US$38.00.<\/p>\n

CoreWeave (CRWV)<\/strong> \u2014 Northland Securities set its price target at US$200.00.<\/p>\n

Corteva (CTVA)<\/strong> \u2014 KeyBanc Capital Markets upgraded its rating to Overweight from Sector Weight with a price target of US$17.00.<\/p>\n

Corteva (CTVA)<\/strong> \u2014 RBC Capital Markets reiterated its Outperform rating and a price target of US$17.00.<\/p>\n

CSX (CSX)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$53.00 from US$54.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

Curtiss-Wright (CW)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$622.00 from US$793.00.<\/p>\n

Dana (DAN)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$36.00 from US$38.00.<\/p>\n

Danaher (DHR)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$255.00 from US$230.00.<\/p>\n

Delek US (DK)<\/strong> \u2014 Freedom Broker initiated coverage with a Hold rating and a price target of US$86.00.<\/p>\n

Delta Air Lines (DAL)<\/strong> \u2014 Bernstein maintained its Outperform rating and lowered its price target to US$100.00 from US$106.00.<\/p>\n

Delta Air Lines (DAL)<\/strong> \u2014 Raymond James reiterated its Outperform rating and a price target of US$100.00.<\/p>\n

Delta Air Lines (DAL)<\/strong> \u2014 Susquehanna maintained its Positive rating and lowered its price target to US$100.00 from US$105.00.<\/p>\n

Devon Energy (DVN)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$61.00 from US$65.00.<\/p>\n

Devon Energy (DVN)<\/strong> \u2014 UBS maintained its Buy rating and raised its price target to US$65.00 from US$63.00.<\/p>\n

Dexcom (DXCM)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$115.00.<\/p>\n

DraftKings (DKNG)<\/strong> \u2014 Guggenheim maintained its Buy rating and lowered its price target to US$30.00 from US$33.00.<\/p>\n

DuPont de Nemours (DD)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$162.00 from US$170.00.<\/p>\n

e.l.f. Beauty (ELF)<\/strong> \u2014 Baird maintained its Outperform rating and raised its price target to US$120.00 from US$105.00.<\/p>\n

Eagle Bancorp (EGBN)<\/strong> \u2014 Hovde Group initiated coverage with an Outperform rating and a price target of US$37.00.<\/p>\n

Ecopetrol (EC)<\/strong> \u2014 Goldman Sachs reiterated its Neutral rating and a price target of US$17.70.<\/p>\n

Edwards Lifesciences (EW)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$110.00.<\/p>\n

Elevance Health (ELV)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$469.00 from US$457.00.<\/p>\n

Eli Lilly and Company (LLY)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and raised its price target to US$1,430.00 from US$1,419.00.<\/p>\n

ENI (E)<\/strong> \u2014 BNP Paribas Exane downgraded its rating to Neutral from Outperform with a price target of US$56.30.<\/p>\n

Enova International (ENVA)<\/strong> \u2014 Jefferies maintained its Buy rating and lowered its price target to US$275.00 from US$300.00.<\/p>\n

Entegris (ENTG)<\/strong> \u2014 Stifel set its price target at US$200.00.<\/p>\n

Equitable (EQH)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$61.00 from US$52.00.<\/p>\n

Equitable (EQH)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$66.00 from US$67.00.<\/p>\n

Everest Group (EG)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$398.00 from US$416.00.<\/p>\n

EVgo (EVGO)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$2.00 from US$3.00.<\/p>\n

Expedia Group (EXPE)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$275.00 from US$307.00.<\/p>\n

F&G Annuities & Life (FG)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$24.00 from US$27.00.<\/p>\n

Federal Realty Investment Trust (FRT)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating.<\/p>\n

FedEx (FDX)<\/strong> \u2014 Citigroup maintained its Buy rating and raised its price target to US$373.00 from US$359.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

FedEx (FDX)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$350.00 from US$365.00.<\/p>\n

FedEx Freight (FDXF)<\/strong> \u2014 BMO Capital Markets set its price target at US$130.00.<\/p>\n

FedEx Freight (FDXF)<\/strong> \u2014 Truist Securities maintained its Hold rating and lowered its price target to US$115.00 from US$155.00.<\/p>\n

Ferguson (FERG)<\/strong> \u2014 RBC Capital Markets maintained its Outperform rating and lowered its price target to US$286.00 from US$290.00.<\/p>\n

Figure Technology Solutions (FIGR)<\/strong> \u2014 Goldman Sachs set its price target at US$41.00.<\/p>\n

Figure Technology Solutions (FIGR)<\/strong> \u2014 Needham reiterated its Buy rating.<\/p>\n

Flowers Foods (FLO)<\/strong> \u2014 BNP Paribas Exane maintained its Underperform rating and lowered its price target to US$5.00 from US$6.50.<\/p>\n

Flutter Entertainment (FLUT)<\/strong> \u2014 Citigroup upgraded its rating to Buy from Neutral and lowered its price target to US$91.00 from US$93.00.<\/p>\n

Ford Motor (F)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$15.00 from US$17.00.<\/p>\n

Fortune Brands Innovations (FBIN)<\/strong> \u2014 RBC Capital Markets maintained its Outperform rating and lowered its price target to US$49.00 from US$57.00.<\/p>\n

Fossil Group (FOSL)<\/strong> \u2014 Lake Street Capital initiated coverage with a Buy rating and a price target of US$10.00.<\/p>\n

Franklin Resources (BEN)<\/strong> \u2014 UBS resumed coverage with a Buy rating and raised its price target to US$40.00 from US$23.00.<\/p>\n

Freeport-McMoRan (FCX)<\/strong> \u2014 JPMorgan maintained its Overweight rating and raised its price target to US$92.00 from US$77.00.<\/p>\n

Freeport-McMoRan (FCX)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$75.00 from US$70.00.<\/p>\n

Frontier Group (ULCC)<\/strong> \u2014 Susquehanna maintained its Neutral rating and lowered its price target to US$6.00 from US$7.00.<\/p>\n

GE HealthCare (GEHC)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$85.00.<\/p>\n

General Dynamics (GD)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$374.00 from US$404.00.<\/p>\n

General Motors (GM)<\/strong> \u2014 Truist Securities set its price target at US$105.00.<\/p>\n

General Motors (GM)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$112.00 from US$114.00.<\/p>\n

Genmab A\/S (GMAB)<\/strong> \u2014 H.C. Wainwright maintained its Buy rating and raised its price target to US$50.00 from US$40.00.<\/p>\n

Genmab A\/S (GMAB)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$45.00 from US$40.00.<\/p>\n

Gentex (GNTX)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$24.00 from US$25.00.<\/p>\n

Gilead Sciences (GILD)<\/strong> \u2014 JPMorgan maintained its Overweight rating and raised its price target to US$170.00 from US$160.00.<\/p>\n

Gilead Sciences (GILD)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$163.00 from US$165.00.<\/p>\n

Gilead Sciences (GILD)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$158.00 from US$150.00.<\/p>\n

Group 1 Automotive (GPI)<\/strong> \u2014 KeyBanc Capital Markets set its price target at US$425.00.<\/p>\n

Group 1 Automotive (GPI)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$271.00 from US$330.00.<\/p>\n

Groupon (GRPN)<\/strong> \u2014 Goldman Sachs set its price target at US$16.00.<\/p>\n

Guardant Health (GH)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$220.00 from US$200.00.<\/p>\n

Gulfport Energy (GPOR)<\/strong> \u2014 Mizuho set its price target at US$237.00.<\/p>\n

Halozyme Therapeutics (HALO)<\/strong> \u2014 H.C. Wainwright reiterated its Buy rating.<\/p>\n

Harrow (HROW)<\/strong> \u2014 BTIG Research reiterated its Buy rating and a price target of US$63.00.<\/p>\n

HCA Healthcare (HCA)<\/strong> \u2014 RBC Capital Markets maintained its Outperform rating and raised its price target to US$496.00 from US$435.00.<\/p>\n

Honeywell Aerospace (HONA)<\/strong> \u2014 Goldman Sachs initiated coverage with a Neutral rating and a price target of US$190.00.<\/p>\n

Hormel Foods (HRL)<\/strong> \u2014 BNP Paribas Exane reiterated its Neutral rating and lowered its price target to US$23.00 from US$26.00.<\/p>\n

Houlihan Lokey (HLI)<\/strong> \u2014 UBS maintained its Neutral rating and raised its price target to US$154.00 from US$147.00.<\/p>\n

Howmet Aerospace (HWM)<\/strong> \u2014 Bernstein reiterated its Outperform rating and a price target of US$298.00.<\/p>\n

HubSpot (HUBS)<\/strong> \u2014 Cantor Fitzgerald reiterated its Neutral rating and a price target of US$200.00.<\/p>\n

Humacyte (HUMA)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$0.50.<\/p>\n

Humana (HUM)<\/strong> \u2014 Cantor Fitzgerald upgraded its rating to Overweight from Neutral and raised its price target to US$460.00 from US$300.00.<\/p>\n

Humana (HUM)<\/strong> \u2014 Raymond James set its price target at US$460.00.<\/p>\n

Hut 8 (HUT)<\/strong> \u2014 Canaccord Genuity reiterated its Buy rating and a price target of US$130.00.<\/p>\n

Hut 8 (HUT)<\/strong> \u2014 Roth Capital set its price target at US$108.00.<\/p>\n

Iamgold (IAG)<\/strong> \u2014 Freedom Broker initiated coverage with a Buy rating and a price target of US$23.00.<\/p>\n

Illumina (ILMN)<\/strong> \u2014 Barclays maintained its Underweight rating and raised its price target to US$200.00 from US$160.00.<\/p>\n

IMAX (IMAX)<\/strong> \u2014 UBS set its price target at US$65.00.<\/p>\n

Inspire Medical Systems (INSP)<\/strong> \u2014 Barclays initiated coverage with an Underweight rating and a price target of US$65.00.<\/p>\n

Installed Building Products (IBP)<\/strong> \u2014 RBC Capital Markets maintained its Sector Perform rating and lowered its price target to US$208.00 from US$228.00.<\/p>\n

Insulet (PODD)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$150.00.<\/p>\n

Interactive Brokers Group (IBKR)<\/strong> \u2014 Barclays reiterated its Overweight rating and raised its price target to US$115.00 from US$114.00.<\/p>\n

Interactive Brokers Group (IBKR)<\/strong> \u2014 UBS reiterated its Neutral rating and lowered its price target to US$101.00 from US$102.00.<\/p>\n

Intercontinental Exchange (ICE)<\/strong> \u2014 Barclays reiterated its Overweight rating and raised its price target to US$189.00 from US$182.00.<\/p>\n

Intercontinental Exchange (ICE)<\/strong> \u2014 Keefe, Bruyette & Woods reiterated its Outperform rating.<\/p>\n

International Flavors & Fragrances (IFF)<\/strong> \u2014 Argus maintained its Buy rating and raised its price target to US$95.00 from US$85.00.<\/p>\n

International Flavors & Fragrances (IFF)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$100.00 from US$101.00.<\/p>\n

International Paper (IP)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$42.00 from US$46.00.<\/p>\n

Intuitive Surgical (ISRG)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$485.00.<\/p>\n

Invesco (IVZ)<\/strong> \u2014 UBS resumed coverage with a Buy rating and a price target of US$41.00.<\/p>\n

IQVIA (IQV)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$300.00 from US$275.00.<\/p>\n

IQVIA (IQV)<\/strong> \u2014 Mizuho maintained its Outperform rating and raised its price target to US$300.00 from US$275.00.<\/p>\n

Ispire Technology (ISPR)<\/strong> \u2014 BTIG Research set its price target at US$3.30.<\/p>\n

J.B. Hunt Transport Services (JBHT)<\/strong> \u2014 BMO Capital Markets set its price target at US$315.00.<\/p>\n

J.B. Hunt Transport Services (JBHT)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$254.00 from US$309.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

J.B. Hunt Transport Services (JBHT)<\/strong> \u2014 Truist Securities maintained its Hold rating and lowered its price target to US$235.00 from US$295.00.<\/p>\n

Jackson Financial (JXN)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$150.00 from US$149.00.<\/p>\n

Jazz Pharmaceuticals (JAZZ)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$286.00 from US$281.00.<\/p>\n

Jersey Mike’s (JMKE)<\/strong> \u2014 TD Cowen maintained its Buy rating and lowered its price target to US$22.00 from US$26.00.<\/p>\n

JetBlue Airways (JBLU)<\/strong> \u2014 Susquehanna maintained its Neutral rating and lowered its price target to US$4.00 from US$6.00.<\/p>\n

Johnson & Johnson (JNJ)<\/strong> \u2014 Guggenheim reiterated its Buy rating and a price target of US$287.00.<\/p>\n

Johnson Controls International (JCI)<\/strong> \u2014 Bernstein reiterated its Outperform rating.<\/p>\n

Kimco Realty (KIM)<\/strong> \u2014 Goldman Sachs set its price target at US$24.00.<\/p>\n

Kinsale Capital Group (KNSL)<\/strong> \u2014 Cantor Fitzgerald maintained its Neutral rating and raised its price target to US$264.00 from US$259.00.<\/p>\n

Knight-Swift Transportation (KNX)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$81.00 from US$90.00.<\/p>\n

Kroger (KR)<\/strong> \u2014 BNP Paribas Exane upgraded its rating to Outperform from Neutral with a price target of US$72.00.<\/p>\n

Lamb Weston (LW)<\/strong> \u2014 Deutsche Bank reiterated its Hold rating and a price target of US$53.00.<\/p>\n

Lamb Weston (LW)<\/strong> \u2014 JPMorgan maintained its Neutral rating and raised its price target to US$53.00 from US$46.00.<\/p>\n

Lamb Weston (LW)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and lowered its price target to US$54.00 from US$57.00.<\/p>\n

Landstar System (LSTR)<\/strong> \u2014 Truist Securities maintained its Hold rating and lowered its price target to US$175.00 from US$185.00.<\/p>\n

Lazard (LAZ)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$40.00 from US$44.00.<\/p>\n

Lear (LEA)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$132.00 from US$141.00.<\/p>\n

Leidos (LDOS)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$141.00 from US$161.00.<\/p>\n

Lennar (LEN)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$75.00 from US$80.00.<\/p>\n

Lincoln National (LNC)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$48.00 from US$45.00.<\/p>\n

Lincoln National (LNC)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$49.00 from US$53.00.<\/p>\n

Lincoln National (LNC)<\/strong> \u2014 National Bank Financial set its price target at US$49.00.<\/p>\n

Linde (LIN)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$560.00 from US$580.00.<\/p>\n

Lithia Motors (LAD)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$335.00 from US$440.00.<\/p>\n

LivaNova (LIVN)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$105.00.<\/p>\n

Live Oak Bancshares (LOB)<\/strong> \u2014 Piper Sandler maintained its Neutral rating and lowered its price target to US$38.00 from US$46.00.<\/p>\n

LPL Financial (LPLA)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$409.00 from US$401.00.<\/p>\n

LPL Financial (LPLA)<\/strong> \u2014 JPMorgan maintained its Overweight rating and raised its price target to US$445.00 from US$428.00.<\/p>\n

LPL Financial (LPLA)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$390.00 from US$391.00.<\/p>\n

M&T Bank (MTB)<\/strong> \u2014 Raymond James initiated coverage with an Outperform rating and a price target of US$250.00.<\/p>\n

MannKind (MNKD)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$5.00 from US$6.00.<\/p>\n

Marex Group plc Ordinary Shares (MRX)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$92.00 from US$86.00.<\/p>\n

Marsh & McLennan Companies (MRSH)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$190.00 from US$201.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 BMO Capital Markets reiterated its Market Perform rating and a price target of US$325.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Cantor Fitzgerald maintained its Neutral rating and raised its price target to US$350.00 from US$330.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Craig-Hallum reiterated its Buy rating and a price target of US$380.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Goldman Sachs reiterated its Neutral rating and a price target of US$270.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 JPMorgan maintained its Overweight rating and raised its price target to US$360.00 from US$305.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 KeyBanc Capital Markets reiterated its Overweight rating.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$300.00 from US$268.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Needham maintained its Buy rating and raised its price target to US$400.00 from US$300.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Oppenheimer reiterated its Outperform rating and a price target of US$425.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Piper Sandler maintained its Overweight rating and raised its price target to US$400.00 from US$270.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 RBC Capital Markets maintained its Outperform rating and raised its price target to US$425.00 from US$360.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Stifel maintained its Buy rating and raised its price target to US$370.00 from US$350.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Susquehanna maintained its Positive rating and raised its price target to US$340.00 from US$265.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 TD Cowen upgraded its rating to Buy from Hold and raised its price target to US$350.00 from US$245.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 UBS maintained its Buy rating and raised its price target to US$350.00 from US$335.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and raised its price target to US$365.00 from US$310.00.<\/p>\n

Marvell Technology (MRVL)<\/strong> \u2014 Wolfe Research maintained its Outperform rating and raised its price target to US$375.00 from US$280.00.<\/p>\n

Masco (MAS)<\/strong> \u2014 RBC Capital Markets maintained its Sector Perform rating and lowered its price target to US$69.00 from US$72.00.<\/p>\n

MasTec (MTZ)<\/strong> \u2014 Mizuho set its price target at US$352.00.<\/p>\n

McKesson (MCK)<\/strong> \u2014 Leerink Partners maintained its Outperform rating and raised its price target to US$1,070.00 from US$1,030.00.<\/p>\n

Medpace (MEDP)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$625.00 from US$600.00.<\/p>\n

Medpace (MEDP)<\/strong> \u2014 Mizuho maintained its Outperform rating and raised its price target to US$700.00 from US$665.00.<\/p>\n

Medtronic (MDT)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$95.00.<\/p>\n

Merck & Co., Inc. (MRK)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$177.00 from US$179.00.<\/p>\n

MetLife (MET)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$111.00 from US$97.00.<\/p>\n

MetLife (MET)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$109.00 from US$112.00.<\/p>\n

Mettler-Toledo International (MTD)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$1,700.00 from US$1,575.00.<\/p>\n

Micron Technology (MU)<\/strong> \u2014 DA Davidson maintained its Buy rating and raised its price target to US$3,000.00 from US$2,100.00.<\/p>\n

MiniMed Group (MMED)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$22.00.<\/p>\n

Mobileye Global (MBLY)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$7.50 from US$9.00.<\/p>\n

Moderna (MRNA)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$95.00 from US$89.00.<\/p>\n

Moelis & Company (MC)<\/strong> \u2014 UBS upgraded its rating to Neutral from Sell and lowered its price target to US$59.00 from US$60.00.<\/p>\n

Mohawk Industries (MHK)<\/strong> \u2014 RBC Capital Markets downgraded its rating to Underperform from Sector Perform and lowered its price target to US$112.00 from US$130.00.<\/p>\n

Moody’s (MCO)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$470.00 from US$512.00.<\/p>\n

MP Materials (MP)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$66.00 from US$73.00.<\/p>\n

Nasdaq (NDAQ)<\/strong> \u2014 Barclays reiterated its Overweight rating and lowered its price target to US$109.00 from US$111.00.<\/p>\n

Natera (NTRA)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$475.00 from US$340.00.<\/p>\n

Nayax (NYAX)<\/strong> \u2014 Jefferies reiterated its Buy rating and a price target of US$68.30.<\/p>\n

NeoGenomics (NEO)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating.<\/p>\n

Neostellar Capital (NSLR)<\/strong> \u2014 BTIG Research maintained its Buy rating and lowered its price target to US$14.00 from US$15.00.<\/p>\n

Neptune Insurance (NP)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$31.00 from US$32.00.<\/p>\n

NetApp (NTAP)<\/strong> \u2014 Cantor Fitzgerald upgraded its rating to Overweight.<\/p>\n

NetApp (NTAP)<\/strong> \u2014 Evercore ISI upgraded its rating to Outperform from In-Line with a price target of US$300.00.<\/p>\n

NetApp (NTAP)<\/strong> \u2014 Loop Capital set its price target at US$300.00.<\/p>\n

Netflix (NFLX)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$70.00 from US$80.00.<\/p>\n

New Era Energy & Digital (NUAI)<\/strong> \u2014 Roth Capital initiated coverage with a Buy rating and a price target of US$10.00.<\/p>\n

Nexa Resources (NEXA)<\/strong> \u2014 Morgan Stanley upgraded its rating to Overweight from Equal Weight with a price target of US$14.20.<\/p>\n

Nextpower (NXT)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$121.00 from US$132.00.<\/p>\n

nLight (LASR)<\/strong> \u2014 Northcoast Research upgraded its rating to Buy from Neutral with a price target of US$75.00.<\/p>\n

Nomad Foods (NOMD)<\/strong> \u2014 Deutsche Bank reiterated its Hold rating and a price target of US$12.00.<\/p>\n

Norfolk Southern (NSC)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$347.00 from US$376.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

OKYO Pharma (OKYO)<\/strong> \u2014 H.C. Wainwright reiterated its Buy rating.<\/p>\n

Old Dominion Freight Line (ODFL)<\/strong> \u2014 BMO Capital Markets set its price target at US$235.00.<\/p>\n

Old Dominion Freight Line (ODFL)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$230.00 from US$250.00.<\/p>\n

Old Dominion Freight Line (ODFL)<\/strong> \u2014 Wolfe Research upgraded its rating to Peer Perform from Underperform.<\/p>\n

OmniAb (OABI)<\/strong> \u2014 Leerink Partners maintained its Outperform rating and raised its price target to US$12.00 from US$10.00.<\/p>\n

ONE Gas (OGS)<\/strong> \u2014 Jefferies downgraded its rating to Hold from Buy with a price target of US$80.00.<\/p>\n

Oportun Financial (OPRT)<\/strong> \u2014 Jefferies maintained its Hold rating and raised its price target to US$9.00 from US$6.00.<\/p>\n

Option Care Health (OPCH)<\/strong> \u2014 Barrington Research changed its rating to Market Perform from Outperform.<\/p>\n

Option Care Health (OPCH)<\/strong> \u2014 Citizens JMP Securities changed its rating to Market Perform from Market Outperform.<\/p>\n

Option Care Health (OPCH)<\/strong> \u2014 JPMorgan changed its rating to Neutral from Overweight with a price target of US$33.00.<\/p>\n

Option Care Health (OPCH)<\/strong> \u2014 Truist Securities set its price target at US$32.05.<\/p>\n

Oruka Therapeutics (ORKA)<\/strong> \u2014 Piper Sandler reiterated its Overweight rating.<\/p>\n

Owens Corning (OC)<\/strong> \u2014 RBC Capital Markets downgraded its rating to Sector Perform from Outperform and lowered its price target to US$127.00 from US$172.00.<\/p>\n

Owens Corning (OC)<\/strong> \u2014 Vertical Research downgraded its rating to Sell from Hold with a price target of US$106.00.<\/p>\n

Pacira BioSciences (PCRX)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$31.00 from US$30.00.<\/p>\n

Packaging Corporation of America (PKG)<\/strong> \u2014 Wells Fargo maintained its Equal Weight rating and lowered its price target to US$245.00 from US$246.00.<\/p>\n

Pembina Pipeline (PBA)<\/strong> \u2014 Barclays reiterated its Overweight rating.<\/p>\n

Penguin Solutions (PENG)<\/strong> \u2014 Barclays maintained its Underweight rating and raised its price target to US$60.00 from US$40.00.<\/p>\n

Penguin Solutions (PENG)<\/strong> \u2014 Goldman Sachs reiterated its Buy rating and a price target of US$85.00.<\/p>\n

Penguin Solutions (PENG)<\/strong> \u2014 Needham maintained its Buy rating and raised its price target to US$85.00 from US$80.00.<\/p>\n

Penguin Solutions (PENG)<\/strong> \u2014 Rosenblatt Securities maintained its Buy rating and raised its price target to US$100.00 from US$80.00.<\/p>\n

Penguin Solutions (PENG)<\/strong> \u2014 Stifel maintained its Buy rating and raised its price target to US$85.00 from US$75.00.<\/p>\n

Phillips Edison & Company, Inc. (PECO)<\/strong> \u2014 Goldman Sachs set its price target at US$44.00.<\/p>\n

PHINIA (PHIN)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$68.00 from US$80.00.<\/p>\n

PJT Partners (PJT)<\/strong> \u2014 Keefe, Bruyette & Woods downgraded its rating to Market Perform from Outperform and lowered its price target to US$159.00 from US$195.00.<\/p>\n

PJT Partners (PJT)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$165.00 from US$176.00.<\/p>\n

Polaris (PII)<\/strong> \u2014 Baird maintained its Neutral rating and lowered its price target to US$65.00 from US$72.00.<\/p>\n

Principal Financial Group (PFG)<\/strong> \u2014 Barclays maintained its Underweight rating and lowered its price target to US$86.00 from US$92.00.<\/p>\n

PROCEPT BioRobotics (PRCT)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$30.00.<\/p>\n

PROG (PRG)<\/strong> \u2014 Jefferies maintained its Buy rating and lowered its price target to US$50.00 from US$60.00.<\/p>\n

Progressive (PGR)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$247.00 from US$246.00.<\/p>\n

Progressive (PGR)<\/strong> \u2014 HSBC reiterated its Hold rating and a price target of US$216.00.<\/p>\n

Prudential Financial (PRU)<\/strong> \u2014 Barclays maintained its Underweight rating and raised its price target to US$96.00 from US$92.00.<\/p>\n

Prudential Financial (PRU)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$109.00 from US$113.00.<\/p>\n

PTC Therapeutics (PTCT)<\/strong> \u2014 RBC Capital Markets reiterated its Sector Perform rating.<\/p>\n

Quanta Services (PWR)<\/strong> \u2014 Mizuho set its price target at US$684.00.<\/p>\n

Quest Diagnostics (DGX)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$260.00 from US$250.00.<\/p>\n

QXO (QXO)<\/strong> \u2014 RBC Capital Markets maintained its Outperform rating and lowered its price target to US$18.00 from US$27.00.<\/p>\n

Raymond James Financial (RJF)<\/strong> \u2014 Barclays reiterated its Overweight rating and raised its price target to US$197.00 from US$196.00.<\/p>\n

Raymond James Financial (RJF)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$179.00 from US$184.00.<\/p>\n

Regeneron Pharmaceuticals (REGN)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$779.00 from US$758.00.<\/p>\n

Regeneron Pharmaceuticals (REGN)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$780.00 from US$772.00.<\/p>\n

Reinsurance Group of America (RGA)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$286.00 from US$290.00.<\/p>\n

Repligen (RGEN)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$225.00 from US$175.00.<\/p>\n

Restaurant Brands International (QSR)<\/strong> \u2014 TD Cowen maintained its Hold rating and lowered its price target to US$78.00 from US$80.00.<\/p>\n

Revolution Medicines (RVMD)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$240.00 from US$239.00.<\/p>\n

Revvity (RVTY)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$160.00 from US$115.00.<\/p>\n

Rezolve AI (RZLV)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

Robinhood Markets (HOOD)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$132.00 from US$105.00.<\/p>\n

Rocket Pharmaceuticals (RCKT)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

Rocket Pharmaceuticals (RCKT)<\/strong> \u2014 Chardan Capital reiterated its Buy rating and a price target of US$11.00.<\/p>\n

Rocket Pharmaceuticals (RCKT)<\/strong> \u2014 Jefferies reiterated its Hold rating and a price target of US$2.95.<\/p>\n

Rocket Pharmaceuticals (RCKT)<\/strong> \u2014 Leerink Partners maintained its Market Perform rating and lowered its price target to US$4.00 from US$7.00.<\/p>\n

Rocket Pharmaceuticals (RCKT)<\/strong> \u2014 Wedbush reiterated its Outperform rating.<\/p>\n

Royal Caribbean Cruises (RCL)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$337.00 from US$340.00.<\/p>\n

Royalty Pharma (RPRX)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and raised its price target to US$67.00 from US$65.00.<\/p>\n

RPM International (RPM)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$116.00 from US$128.00.<\/p>\n

RPM International (RPM)<\/strong> \u2014 RBC Capital Markets maintained its Outperform rating and lowered its price target to US$120.00 from US$128.00.<\/p>\n

RPM International (RPM)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$128.00 from US$142.00.<\/p>\n

RTX (RTX)<\/strong> \u2014 Citigroup reiterated its Buy rating.<\/p>\n

RXO (RXO)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$30.00 from US$28.00.<\/p>\n

Ryan Specialty (RYAN)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$40.00 from US$43.00.<\/p>\n

S&P Global (SPGI)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$477.00 from US$525.00.<\/p>\n

Saia (SAIA)<\/strong> \u2014 Citigroup maintained its Buy rating and raised its price target to US$429.00 from US$417.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

SailPoint (SAIL)<\/strong> \u2014 Jefferies reiterated its Buy rating.<\/p>\n

SailPoint (SAIL)<\/strong> \u2014 Oppenheimer initiated coverage with an Outperform rating and a price target of US$30.00.<\/p>\n

Savara (SVRA)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

Savara (SVRA)<\/strong> \u2014 JPMorgan initiated coverage with an Overweight rating and a price target of US$12.00.<\/p>\n

Savara (SVRA)<\/strong> \u2014 RBC Capital Markets set its price target at US$10.00.<\/p>\n

Schneider National (SNDR)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$33.00 from US$38.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

Sensata Technologies (ST)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$54.00 from US$57.00.<\/p>\n

Senseonics Holdings, Inc. Common Stock (SENS)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$10.00.<\/p>\n

ServiceNow (NOW)<\/strong> \u2014 Argus maintained its Buy rating and raised its price target to US$170.00 from US$134.00.<\/p>\n

Simulations Plus (SLP)<\/strong> \u2014 BTIG Research reiterated its Neutral rating.<\/p>\n

SiteOne Landscape Supply (SITE)<\/strong> \u2014 RBC Capital Markets maintained its Outperform rating and lowered its price target to US$124.00 from US$135.00.<\/p>\n

SiteOne Landscape Supply (SITE)<\/strong> \u2014 William Blair reiterated its Market Perform rating.<\/p>\n

Skydance (SKYD)<\/strong> \u2014 Barclays maintained its Underweight rating and lowered its price target to US$7.00 from US$8.00.<\/p>\n

SM Energy (SM)<\/strong> \u2014 Mizuho set its price target at US$39.00.<\/p>\n

SM Energy (SM)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$48.00 from US$43.00.<\/p>\n

SolarEdge Technologies (SEDG)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$36.00 from US$37.00.<\/p>\n

Solstice Advance Materials (SOLS)<\/strong> \u2014 Seaport Research Partners initiated coverage with a Buy rating and a price target of US$80.00.<\/p>\n

Sonic Automotive (SAH)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$74.00 from US$107.00.<\/p>\n

Southern Copper (SCCO)<\/strong> \u2014 Morgan Stanley reiterated its Underweight rating and a price target of US$170.00.<\/p>\n

Southwest Airlines (LUV)<\/strong> \u2014 Susquehanna maintained its Neutral rating and lowered its price target to US$45.00 from US$50.00.<\/p>\n

SpaceX (SPCX)<\/strong> \u2014 Susquehanna maintained its Neutral rating and raised its price target to US$173.00 from US$144.00.<\/p>\n

Stevanato Group (STVN)<\/strong> \u2014 Deutsche Bank initiated coverage with a Hold rating.<\/p>\n

Stifel Financial (SF)<\/strong> \u2014 UBS reiterated its Buy rating and lowered its price target to US$84.00 from US$90.00.<\/p>\n

Stryker (SYK)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$375.00.<\/p>\n

Stryker (SYK)<\/strong> \u2014 Bernstein reiterated its Market Perform rating.<\/p>\n

Sun Life Financial (SLF)<\/strong> \u2014 Barclays reiterated its Underweight rating.<\/p>\n

Sunshine Silver Mining & Refining (SSMR)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$20.00 from US$23.00.<\/p>\n

T. Rowe Price (TROW)<\/strong> \u2014 UBS resumed coverage with a Neutral rating and a price target of US$107.00.<\/p>\n

Tandem Diabetes Care (TNDM)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$18.00.<\/p>\n

Tanger (SKT)<\/strong> \u2014 Goldman Sachs set its price target at US$40.00.<\/p>\n

TE Connectivity (TEL)<\/strong> \u2014 UBS maintained its Buy rating and raised its price target to US$253.00 from US$241.00.<\/p>\n

Textron (TXT)<\/strong> \u2014 Citigroup reiterated its Neutral rating and lowered its price target to US$86.00 from US$99.00.<\/p>\n

TFI International (TFII)<\/strong> \u2014 BMO Capital Markets reiterated its Market Perform rating.<\/p>\n

TFI International (TFII)<\/strong> \u2014 Citigroup maintained its Buy rating and a price target of US$100.00.<\/p>\n

The Hartford Insurance Group (HIG)<\/strong> \u2014 Cantor Fitzgerald maintained its Overweight rating and raised its price target to US$145.00 from US$144.00.<\/p>\n

The Hartford Insurance Group (HIG)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$144.00 from US$154.00.<\/p>\n

TransMedics Group (TMDX)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a price target of US$120.00.<\/p>\n

Twist Bioscience (TWST)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$215.00 from US$112.00.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

Uber Technologies (UBER)<\/strong> \u2014 Citizens JMP Securities reiterated its Market Outperform rating and a price target of US$100.00.<\/p>\n

Union Pacific (UNP)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$338.00 from US$349.00. An additional same-day entry listed a Cautious outlook without a target.<\/p>\n

United Airlines (UAL)<\/strong> \u2014 Susquehanna maintained its Positive rating and lowered its price target to US$150.00 from US$165.00.<\/p>\n

United Parcel Service (UPS)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$122.00 from US$132.00.<\/p>\n

United Parcel Service (UPS)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$115.00 from US$130.00.<\/p>\n

United Therapeutics (UTHR)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$566.00 from US$515.00.<\/p>\n

Unum Group (UNM)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$109.00 from US$110.00.<\/p>\n

UWM (UWMC)<\/strong> \u2014 Keefe, Bruyette & Woods downgraded its rating to Market Perform from Outperform with a price target of US$1.50.<\/p>\n

Vale (VALE)<\/strong> \u2014 Morgan Stanley set its price target at US$15.50.<\/p>\n

Venture Global (VG)<\/strong> \u2014 RBC Capital Markets reiterated its Outperform rating.<\/p>\n

Via Transportation (VIA)<\/strong> \u2014 Deutsche Bank reiterated its Buy rating and a price target of US$35.00.<\/p>\n

Viking Therapeutics (VKTX)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$85.00 from US$87.00.<\/p>\n

Vir Biotechnology (VIR)<\/strong> \u2014 H.C. Wainwright maintained its Buy rating and raised its price target to US$22.00 from US$20.00.<\/p>\n

Visteon (VC)<\/strong> \u2014 UBS set its price target at US$107.00.<\/p>\n

Voya Financial (VOYA)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$109.00 from US$105.00.<\/p>\n

VSE (VSEC)<\/strong> \u2014 Citigroup reiterated its Buy rating.<\/p>\n

Vylor (VYLR)<\/strong> \u2014 KeyBanc Capital Markets initiated coverage with a Sector Weight rating and a price target of US$78.00.<\/p>\n

W.R. Berkley (WRB)<\/strong> \u2014 Cantor Fitzgerald maintained its Neutral rating and raised its price target to US$74.00 from US$73.00.<\/p>\n

W.R. Berkley (WRB)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$70.00 from US$72.00.<\/p>\n

Waters (WAT)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$500.00 from US$460.00.<\/p>\n

Wealthfront (WLTH)<\/strong> \u2014 Goldman Sachs reiterated its Neutral rating and a price target of US$11.00.<\/p>\n

Wealthfront (WLTH)<\/strong> \u2014 Needham reiterated its Buy rating and a price target of US$13.00.<\/p>\n

Werner Enterprises (WERN)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$37.00 from US$43.00.<\/p>\n

West Pharmaceutical Services (WST)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$440.00 from US$400.00.<\/p>\n

Whirlpool (WHR)<\/strong> \u2014 RBC Capital Markets maintained its Underperform rating and lowered its price target to US$22.00 from US$32.00.<\/p>\n

Willis Towers Watson Public (WTW)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$332.00 from US$303.00.<\/p>\n

Willis Towers Watson Public (WTW)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$349.00 from US$380.00.<\/p>\n

XPO (XPO)<\/strong> \u2014 BMO Capital Markets reiterated its Outperform rating.<\/p>\n

XPO (XPO)<\/strong> \u2014 Citigroup upgraded its rating to Buy from Neutral and raised its price target to US$224.00 from US$220.00.<\/p>\n

XPO (XPO)<\/strong> \u2014 Truist Securities maintained its Buy rating and lowered its price target to US$220.00 from US$240.00.<\/p>\n

Yum! Brands (YUM)<\/strong> \u2014 TD Cowen maintained its Buy rating and lowered its price target to US$177.00 from US$180.00.<\/p>\n

Zimmer Biomet (ZBH)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a price target of US$100.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Baird maintained its Outperform rating and raised its price target to US$285.00 from US$230.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$225.00 from US$220.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 BNP Paribas Exane reiterated its Outperform rating and raised its price target to US$250.00 from US$230.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 BTIG Research reiterated its Neutral rating.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Canaccord Genuity maintained its Buy rating and raised its price target to US$250.00 from US$210.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Cantor Fitzgerald maintained its Overweight rating and raised its price target to US$275.00 from US$225.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Citigroup maintained its Buy rating and raised its price target to US$245.00 from US$205.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Guggenheim maintained its Buy rating and raised its price target to US$254.00 from US$214.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Jefferies maintained its Buy rating and raised its price target to US$250.00 from US$220.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 JPMorgan maintained its Overweight rating and raised its price target to US$245.00 from US$215.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Mizuho set its price target at US$235.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$185.00 from US$165.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Needham maintained its Buy rating and raised its price target to US$255.00 from US$215.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 RBC Capital Markets reiterated its Outperform rating and a price target of US$236.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Rosenblatt Securities set its price target at US$250.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Scotiabank maintained its Sector Outperform rating and raised its price target to US$255.00 from US$240.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Stephens maintained its Overweight rating and raised its price target to US$265.00 from US$225.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Stifel maintained its Buy rating and raised its price target to US$235.00 from US$200.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$230.00 from US$200.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Truist Securities reiterated its Buy rating and raised its price target to US$250.00 from US$200.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Wedbush maintained its Outperform rating and raised its price target to US$240.00 from US$215.00.<\/p>\n

Zscaler (ZS)<\/strong> \u2014 Wells Fargo maintained its Overweight rating and raised its price target to US$260.00 from US$215.00.<\/p>\n

Zymeworks (ZYME)<\/strong> \u2014 Truist Securities maintained its Buy rating and raised its price target to US$34.00 from US$32.00.<\/p>\n","protected":false},"excerpt":{"rendered":"

Analyst Ratings (USA) American analyst updates for today show selective optimism in AI infrastructure, cybersecurity and healthcare, alongside caution across transportation, housing-related businesses and…<\/p>\n","protected":false},"author":3,"featured_media":34895,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-76092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"\nU.S. Analyst Updates: October 7th, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. Analyst Updates: October 7th, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) American analyst updates for today show selective optimism in AI infrastructure, cybersecurity and healthcare, alongside caution across transportation, housing-related businesses and…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-08T04:18:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/05\/STA-Frame-42.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"34 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"U.S. Analyst Updates: October 7th, 2026\",\"datePublished\":\"2026-10-08T04:18:05+00:00\",\"dateModified\":\"2026-10-08T04:18:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/\"},\"wordCount\":7652,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/\",\"name\":\"U.S. Analyst Updates: October 7th, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-10-08T04:18:05+00:00\",\"dateModified\":\"2026-10-08T04:18:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. Analyst Updates: October 7th, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"U.S. Analyst Updates: October 7th, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/","og_locale":"en_US","og_type":"article","og_title":"U.S. Analyst Updates: October 7th, 2026","og_description":"Analyst Ratings (USA) American analyst updates for today show selective optimism in AI infrastructure, cybersecurity and healthcare, alongside caution across transportation, housing-related businesses and…","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-10-08T04:18:05+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/05\/STA-Frame-42.png","type":"image\/png"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"34 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"U.S. Analyst Updates: October 7th, 2026","datePublished":"2026-10-08T04:18:05+00:00","dateModified":"2026-10-08T04:18:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/"},"wordCount":7652,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/","name":"U.S. Analyst Updates: October 7th, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-10-08T04:18:05+00:00","dateModified":"2026-10-08T04:18:05+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-7th-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"U.S. Analyst Updates: October 7th, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=76092"}],"version-history":[{"count":4,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76092\/revisions"}],"predecessor-version":[{"id":76098,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76092\/revisions\/76098"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/34895"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=76092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=76092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=76092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}